As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up ...

The partners said their antibody-drug conjugate datopotomab deruxtecan didn’t extend survival in a breast cancer study, ...

Daiichi Sankyo has launched a new direct-to-consumer (DTC) campaign for Enhertu — the first DTC effort for its oncology unit ...

Enhertu is forecast to retain its dominant market position in the ADC landscape and reach global sales of $11.2bn by 2030.

Daiichi Sankyo and AstraZeneca are padding the case for their antibody-drug conjugate Enhertu with new data demonstrating the ...

Enhertu also improved the time to deterioration for pain and other factors in patients with HR-positive, HER2-low and ...

ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.

The results of the open-label DESTINY-Breast12 trial – reported at the ESMO cancer congress in Barcelona this weekend – ...

WILMINGTON, Del.--(BUSINESS WIRE)--Results from the DESTINY-Breast12 Phase IIIb/IV trial showed that ENHERTU ® (fam-trastuzumab deruxtecan-nxki) demonstrated substantial overall and intracranial ...

AbbVie ABBV announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approving the ...